

SOLIGENIX, INC.  
Form 8-K  
August 19, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 19, 2015

Commission File No. 000-16929

**Soligenix, Inc.**

(Exact name of small business issuer as specified in its charter)

**DELAWARE**

(State or other jurisdiction of

incorporation or organization)

**41-1505029**

(I.R.S. Employer

Identification Number)

**29 Emmons Drive,**

**Suite C-10**

**Princeton, NJ**

**08540**

(Address of principal executive offices) (Zip Code)

**(609) 538-8200**

(Issuer's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On August 19, 2015, Soligenix, Inc. (the “Company”) issued a press release to announce that the National Institute of Allergy and Infectious Diseases has exercised its option for contract #HHSN272201400039C to provide the Company with an additional \$2.7 million in funding to advance the development of the Company’s heat stabilized ricin toxin vaccine, RiVax™. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No. Description**

99.1 Press Release dated August 19, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Soligenix, Inc.**

August 19, 2015 By: /s/ **Christopher J. Schaber**  
Christopher J. Schaber, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)